Matthew H Spitzer
Overview
Explore the profile of Matthew H Spitzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
5275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Babdor J, Patel R, Davidson B, Noecker C, Rahim M, Bisanz J, et al.
bioRxiv
. 2024 Dec;
PMID: 39677657
Human immune systems are highly variable, with most variation attributable to non-genetic sources. The gut microbiome crucially shapes the immune system; however, its relationship with the baseline immune states of...
2.
Cho N, Guldberg S, Nabet B, Yu J, Kim E, Hiam-Galvez K, et al.
Cancer Immunol Res
. 2024 Oct;
13(2):229-244.
PMID: 39404741
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells...
3.
Castillo J, DeBarge R, Mende A, Tenvooren I, Marquez D, Straub A, et al.
Nat Immunol
. 2024 Aug;
25(9):1754-1763.
PMID: 39191945
T cell antigen receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we present a mass cytometric (CyTOF) approach to track T cell...
4.
Roschelle M, Rabbani R, Gweon S, Kumar R, Vercruysse A, Cho N, et al.
ArXiv
. 2024 Jul;
PMID: 38979489
Real-time monitoring of dynamic biological processes in the body is critical to understanding disease progression and treatment response. This data, for instance, can help address the lower than 50% response...
5.
Allen B, Hiam K, Burnett C, Venida A, DeBarge R, Tenvooren I, et al.
Nat Med
. 2024 Apr;
30(5):1502.
PMID: 38565647
No abstract available.
6.
Wai K, Okholm T, Ha P, Marquez D, Tenvooren I, Jones K, et al.
Head Neck
. 2024 Mar;
46(7):1625-1636.
PMID: 38454566
Background: Treatment of salivary gland tumors (SGTs) remains challenging. Little is known about the immune landscape of SGTs. We aimed to characterize the tumor microenvironment in benign and malignant SGTs....
7.
Revach O, Cicerchia A, Shorer O, Petrova B, Anderson S, Park J, et al.
bioRxiv
. 2024 Feb;
PMID: 38405985
A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma. T cell exhaustion, resulting from chronic...
8.
Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, et al.
JCI Insight
. 2024 Feb;
9(7).
PMID: 38386420
The efficacy of chimeric antigen receptor T cell (CAR-T) therapy has been limited against brain tumors to date. CAR-T cells infiltrating syngeneic intracerebral SB28 EGFRvIII gliomas revealed impaired mitochondrial ATP...
9.
Castillo J, DeBarge R, Mende A, Tenvooren I, Marquez D, Straub A, et al.
bioRxiv
. 2024 Jan;
PMID: 38260336
T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different...
10.
Kovacsovics-Bankowski M, Sweere J, Healy C, Sigal N, Cheng L, Chronister W, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38233101
Background: Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe...